Dominik Lock

Title: Dominik Lock: Innovator in Immunotherapy

Introduction

Dominik Lock is a prominent inventor based in Cologne, Germany. He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 2 patents, Lock's work focuses on enhancing the efficacy of immune cells in targeting specific antigens.

Latest Patents

Lock's latest patents include groundbreaking inventions in the realm of chimeric antigen receptors (CAR). The first patent describes a regulatory T (Treg) cell expressing an antigen chimeric receptor. This invention provides a Treg cell that includes an antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain. The Treg cell is designed to specifically bind to antigens expressed on the surface of target cells, offering potential advancements in targeted therapies. The second patent presents an immune effector cell that comprises a CAR specific for a tag of a tagged polypeptide. This immune effector cell also includes a chimeric costimulatory receptor that enhances the immune response triggered by the CAR, thereby improving therapeutic outcomes.

Career Highlights

Throughout his career, Dominik Lock has worked with notable organizations such as Miltenyi Biotec B.V. & Co. KG and Charité-Universitätsmedizin Berlin. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research in immunotherapy.

Collaborations

Lock has collaborated with esteemed colleagues, including Andrew Kaiser and Mario Assenmacher. These partnerships have further enriched his research and development efforts in the field of immunology.

Conclusion

Dominik Lock's innovative work in the development of chimeric antigen receptors and immune effector cells positions him as a key figure in advancing immunotherapy. His contributions are paving the way for more effective treatments in the fight against diseases.